FDA approves roflumilast foam 0.3% for scalp, body psoriasis ...

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc. A new longitudinal study published in JAMA Network ...

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body ...

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older. On May 22, 2025, the FDA approved roflumilast (Zoryve; Arcutis ...

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older. On May 19, 2025, the FDA approved Jivi (antihemophilic factor [recombinant], ...

Victor Carrion, MD, emphasizes how pediatricians can monitor and support mental health in youth while navigating limited access to specialized care. Victor Carrion, MD, director of the Stanford Early ...

Most videos on TikTok regarding hormonal contraception were misleading, according to a study presented at the 2025 ACOG Annual Clinical and Scientific Meeting. Millions turn to TikTok for health ...

In the first season following the introduction of a new maternal respiratory syncytial virus (RSV) vaccine, data presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual ...

Infants born moderately preterm had lower composite cognitive scores compared to those born at full-term s (β = −0.39; 95% CI, −0.55 to −0.22; P < .001).

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes. Approval was based on phase 3 trials showing strong ...

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions. Infants younger than 6 months and premature babies had ...

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study. In part 2 of ...